Vasomotor symptoms, which commonly include hot flashes and night sweats, are the most common symptoms that affect the majority of the women undergoing menopausal transition. Around 80% of menopausal women are reported to experience these symptoms, which usually persist for 7 to 10 years. Vasomotor symptoms of menopause often contribute to sleep and mood issues, that can substantially impact the quality of life. Thus, there is a growing demand for effective treatments offering more targeted relief, which is likely to boost investment and innovation in the drug pipeline.
The Vasomotor Symptoms of Menopause Drug Pipeline Report by Expert Market Research gives comprehensive insights into vasomotor symptoms of menopause drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vasomotor symptoms of menopause. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The vasomotor symptoms of menopause pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from vasomotor symptoms of menopause.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing vasomotor symptoms of menopause pipeline development activities.
Vasomotor symptoms are the primary menopausal symptoms characterized by hot flashes and/or night sweats. These symptoms include episodes of profuse heat along with sweating and flushing, predominantly around the upper parts of the body such as the head, chest, neck, and upper back. Around 4 out of 5 menopausal women experience vasomotor symptoms. Fluctuation in the hormone level, particularly a drop in estrogen, is considered one of the main reasons responsible for vasomotor symptoms.
Hormone replacement therapy is an effective vasomotor symptoms of menopause treatment. Nonhormonal treatments such as fezolinetant (Veozah) or low-dose paroxetine (Paxil, Pexeva) are also prescribed to manage hot flashes or night sweats. Advancements in neurokinin research and the growth in clinical trial activity of investigational drugs that offer targeted relief are anticipated to positively influence the drug pipeline landscape for vasomotor symptoms of menopause in the coming years.
This section of the report covers the analysis of vasomotor symptoms of menopause drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
EMR’s vasomotor symptoms of menopause therapeutic assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The vasomotor symptoms of menopause report cover phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for vasomotor symptoms of menopause.
The drug molecule categories covered under vasomotor symptoms of menopause pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for vasomotor symptoms of menopause.
The EMR vasomotor symptoms of menopause drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in vasomotor symptoms of menopause clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for vasomotor symptoms of menopause. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of vasomotor symptoms of menopause drug candidates.
The objective of this randomized, placebo-controlled, double-blind study is to assess the long-term safety of the drug fezolinetant, a selective neurokinin-3 receptor antagonist, in around 260 Japanese women experiencing vasomotor symptoms associated with menopause. The study is conducted by Astellas Pharma Inc. and is under Phase III clinical development.
Noema Pharma AG is conducting a Phase II multi-center clinical trial to investigate the preliminary efficacy, safety, and tolerability of vasomotor symptoms of menopause drug candidate NOE-115, a triple reuptake inhibitor, in women suffering from the condition. The study has enrolled around 24 patients and is expected to be completed by April 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Vasomotor Symptoms of Menopause Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for vasomotor symptoms of menopause. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into vasomotor symptoms of menopause collaborations, regulatory environments, and potential growth opportunities.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share